This database contains 62 studies, archived under the term: "biological markers"
Click here to filter this large number of results.
A serum protein-based algorithm for the detection of Alzheimer disease
O'Bryant, Sid E.,
Xiao, Guanghua,
Barber, Robert,
Reisch, Joan,
Doody, Rachelle,
Fairchild, Thomas,
Adams, Perrie,
Waring, Steven,
Diaz-Arrastia, Ramon
Objective: To develop an algorithm that separates patients with Alzheimer disease (AD) from controls. Design: Longitudinal case-control study. Setting: The Texas Alzheimer’s Research Consortium project. Patients: We analyzed serum protein-based multiplex biomarker data from 197 patients diagnosed with AD and 203 controls. Main Outcome Measure: The total sample was randomized equally into training and test […]
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative
Ellis, Kathryn A.,
Rowe, Christopher C.,
Villemagne, Victor L.,
Martins, Ralph N.,
Masters, Colin L.,
Salvado, Olivier,
Szoeke, Cassandra,
Ames, David
The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer’s disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and […]
Effects of a controlled trial of aerobic exercise for mild cognitive impairment: A controlled trial
Baker, Laura D.,
Frank, Laura L.,
Foster-Schubert, Karen,
Green, Pattie S.,
Wilkinson, Charles W.,
McTiernan, Anne,
Plymate, Stephen R.,
Fishel, Mark A.,
Watson, G. Stennis,
Cholerton, Brenna A.,
Dunca, Glen E.,
Mehta, Pankaj D.,
Craft, Suzanne
Objectives: To examine the effects of aerobic exercise on cognition and other biomarkers associated with Alzheimer disease pathology for older adults with mild cognitive impairment, and assess the role of sex as a predictor of response. Design: Six-month, randomized, controlled, clinical trial. Setting: Veterans Affairs Puget Sound Health Care System clinical research unit. Participants: Thirty-three […]
The effects of ramipril in individuals at risk for Alzheimer’s disease: results of a pilot clinical trial
Wharton, Whitney,
Stein, James H.,
Korcarz, Claudia,
Sachs, Jane,
Olson, Sandra R.,
Zetterberg, Henrik,
Dowling, Maritza,
Ye, Shuyun,
Gleason, Carey E.,
Underbakke, Gail,
Jacobson, Laura E.,
Johnson, Sterling C.,
Sager, Mark A.,
Asthana, Sanjay,
Carlsson, Cynthia M.
Research shows that certain antihypertensives taken during midlife confer Alzheimer’s disease (AD) related benefits in later life. We conducted a clinical trial to evaluate the extent to which the angiotensin converting enzyme inhibitor (ACE-I), ramipril, affects AD biomarkers including cerebrospinal fluid (CSF) amyloid-β (Aβ) levels and ACE activity, arterial function, and cognition in participants with […]
Dietary antioxidants and dementia in a population-based case-control study among older people in South Germany
von Arnim, Christine A. F.,
Herbolsheimer, Florian,
Nikolaus, Thorsten,
Peter, Richard,
Biesalski, Hans K.,
Ludolph, Albert C.,
Riepe, Matthias,
Nagel, Gabriele
Oxidative stress is believed to play a central role in the pathogenesis of Alzheimer’s disease (AD), a neurodegenerative disease. Antioxidants may prevent the onset AD as high dietary intake of vitamin C and E were reported to be associated with lower risk of the disease. The objective of this study was to evaluate the serum […]
Hormone levels and cognitive function in postmenopausal midlife women
Ryan, Joanne,
Stanczyk, Frank Z.,
Dennerstein, Lorraine,
Mack, Wendy J.,
Clark, Margaret S.,
Szoeke, Cassandra,
Kildea, Daniel,
Henderson, Victor W.
Gonadal hormones may influence cognitive function. Postmenopausal midlife women in the population-based Melbourne Women’s Midlife Health Project cohort were administered a comprehensive battery of neuropsychological tests on two occasions 2 years apart. Participants (n = 148, mean age 60 years) had undergone natural menopause and were not using hormone therapy. Estrone, total and free estradiol, […]
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Portelius, Erik,
Zetterberg, Henrik,
Dean, Robert A.,
Marcil, Alexandre,
Bourgeois, Philippe,
Nutu, Magdalena,
Andreasson, Ulf,
Siemers, Eric,
Mawuenyega, Kwasi G.,
Sigurdson, Wendy C.,
May, Patrick C.,
Paul, Steven M.,
Holtzman, David M.,
Blennow, Kaj,
Bateman, Randall J.
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer’s disease: friend or foe?
Kovacs, Janos,
Pákáski, Magdolna,
Juhasz, Anna,
Feher, Agnes,
Drótos, Gergely,
Fazekas, Csilla Orsike,
Horvath, Tamas Laszlo,
Janka, Zoltan,
Kálmán, János
Throughout the natural progression of Alzheimer’s disease (AD), the body mass index (BMI) decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic effect […]